Industry in brief | Medice, ChromaDex, Nestlé

Industry in brief | Medice, ChromaDex, Nestlé

8 June 2021 - Deborah Wilkes

Medice has hired Uwe Baumann, ChromaDex has announced that its Tru Niagen dietary supplements are now available from Walmart in the US, and Nestlé Health Science is acquiring two brands for people with special nutritional needs.

Medice hires Uwe Baumann

Germany’s Medice has hired Uwe Baumann as managing director with responsibility for its OTC business following the recent acquisition of a majority stake of 60% in herbal medicines specialist Schaper & Brümmer.

Medice, which wants to be one of the leading herbal medicines manufacturers in Europe, said Baumann was a renowned expert in the field.

Baumann spent 17 years as executive board member for global business at Bionorica and has also worked for Novartis and Roche.

Medice announced in April 2021 that it had acquired a majority stake in Germany’s Schaper & Brümmer (click here to read the News story).

Tru Niagen available from Walmart

ChromaDex has announced that Walmart is the first major retailer in the US to sell its Tru Niagen dietary supplements.

Tru Niagen was now available in 3,800 Walmart stores across the US, said ChromaDex, as well as online through

The dietary supplements – which contain nicotinamide riboside and claim to provide “cellular energy and repair” – are available from Walmart in 100mg and 300mg strength versions.

ChromaDex, which describes itself as a “global bioscience company dedicated to healthy ageing”, is conducting research on nicotinamide adenine dinucleotide (NAD+). The company says NAD+ is thought to play an important role in healthy ageing.

The company offers the NAD+ precursor nicotinamide riboside as an ingredient under the Niagen brand name. Niagen is the sole active ingredient of the company’s Tru Niagen dietary supplements.

Nestlé Health Science’s acquisition

Nestlé Health Science is acquiring the Comidamed and Mevalia brands for people with special nutritional needs from Dr. Schär.

Comidamed offers powdered blends for the treatment of phenylketonuria and other rare protein metabolism disorders, while Mevalia offers a range of low-protein products and amino acid mixtures for people with protein metabolism disorders.

Nestlé Health Science said the brands complemented its Vitaflo product portfolio for Inborn Errors of Metabolism (IEM).

The deal with Dr. Schär, which has its headquarters in Italy, includes a manufacturing facility in Rosbach, Germany.

Financial details of the transaction, which is expected to close on 1 July 2021, were not disclosed.

Click tags below for more information on topics:

Medice ChromaDex Nestlé

Back to Industry News

Share this page: